OXFORD CANCER BIOMARKERS LIMITED Financials
- Company number
- SC379069CopyCopy
- Registered office
- C/O Douglas Mcdonald Ca, 2 Octavia Buildings, Kilmacolm PA13 4AE
- Incorporated
- 24/05/2010
Company snapshot
- Status
- Active
- Employees
- 2 (2024)
- Latest financial data
- 2024
- Accounts type
- Total Exemption Full
Financial highlights
Latest reported figures. Okredo holds filed data for 2021–2024.
Net Assets
106.04%vs 20232023: £-37.25K
Total Assets
-28.68%vs 20232023: £592.51K
Cash in Bank
-77.60%vs 20232023: £138.32K
Total Liabilities
-33.30%vs 20232023: £560.09K
Employees
-6vs 20232023: 8
In 2024, OXFORD CANCER BIOMARKERS LIMITED reported net assets of £2.25K. The same filing shows total assets of £422.56K, cash in bank of £30.98K and total liabilities of £373.58K. Reported headcount was 2 in 2024. Total Liabilities fell from £560.09K in 2023 to £373.58K in 2024 (-33.30%). Okredo holds filed figures for 2021–2024; the table below lists every reported indicator by year. See every reported indicator by year.
Financial performance
Pick a measure to see how it has moved across the reported years, with the year-on-year change beneath it.
Net Assets
106.04%from £-37.25K in 2023Year-on-year change
Net Assets as filed for 2021–2024. Every figure in this chart is also in the financial history table.
3-year financial trend (2022–2024)
How the figures OXFORD CANCER BIOMARKERS LIMITED filed moved across the three reported years 2022, 2023 and 2024 — measured end to end rather than year on year.
Net Assets
Increasedvs 2022Cash in Bank
-60.9%vs 2022-37.5% a year compound (CAGR)
Total Assets
-26.7%vs 2022-14.4% a year compound (CAGR)
Total Liabilities
-41.1%vs 2022-23.2% a year compound (CAGR)
Employees
-81.8%vs 2022-9Biggest decrease
Employees-81.8%
11 in 2022 to 2 in 2024
OXFORD CANCER BIOMARKERS LIMITED's filings pull in both directions between 2022 and 2024. The steepest fall came in employee numbers, pointing to a smaller workforce, with cash in bank, total assets and total liabilities falling alongside it. See the full year-by-year figures.
Ratios from the filed figures
Calculated from OXFORD CANCER BIOMARKERS LIMITED's own reported amounts, each shown against the year it was derived from — nothing here is estimated or industry-averaged.
- Net assets to total assets
- 0.53%2024
- Reported net assets divided by reported total assets, for the latest year both were filed. Shows how much of the asset base is not financed by liabilities.
- Liabilities to total assets
- 88.41%2024
- Total liabilities divided by reported total assets, for the latest year both were available. Shows how much of the asset base is funded by obligations.
- Cash to liabilities
- 8.29%2024
- Reported cash in bank divided by total liabilities for the same year. Shows what share of outstanding obligations the reported cash balance would cover.
- Cash to total assets
- 7.33%2024
- Reported cash in bank divided by reported total assets, for the latest year both were filed.
Financial history
Every indicator Okredo tracks, year by year.
Reported financial indicators for OXFORD CANCER BIOMARKERS LIMITED by year. Amounts are as filed; a dash means the figure was not reported for that year.
| Indicator | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Net Assets£ | 830.64K | -69.12K | -37.25K | 2.25K |
| Total Assets£ | 980.38K | 576.18K | 592.51K | 422.56K |
| Cash in Bank£ | 595.96K | 79.32K | 138.32K | 30.98K |
| Total Liabilities£ | 135.11K | 634.15K | 560.09K | 373.58K |
| Employees | 12 | 11 | 8 | 2 |
OXFORD CANCER BIOMARKERS LIMITED financials: frequently asked questions
Answered from this company's own filed figures.
Yes. Okredo holds filed figures for OXFORD CANCER BIOMARKERS LIMITED covering 2021–2024, across 5 reported indicators. The most recent reported year is 2024.
OXFORD CANCER BIOMARKERS LIMITED reported net assets of £2.25K for 2024. That compares with £-37.25K in 2023, a change of 106.04%.
OXFORD CANCER BIOMARKERS LIMITED reported total assets of £422.56K for 2024. That compares with £592.51K in 2023, a change of -28.68%.
OXFORD CANCER BIOMARKERS LIMITED reported cash in bank of £30.98K for 2024. That compares with £138.32K in 2023, a change of -77.60%.
OXFORD CANCER BIOMARKERS LIMITED reported 2 employees in 2024, compared with 8 in 2023.
Between 2022 and 2024, OXFORD CANCER BIOMARKERS LIMITED's cash in bank fell by 60.9%, total assets fell by 26.7%, total liabilities fell by 41.1% and employee numbers fell by 81.8%. Cash in bank contracted at 37.5% a year across the two years to 2024, from £79.32K to £30.98K. Reported headcount went from 11 in 2022 to 2 in 2024 (-9).
Okredo holds reported figures for the years 2021, 2022, 2023, 2024. Where an indicator was not reported for a given year, the financial history table shows a dash rather than a value.